A Randomized, Double-blind, Placebo-Controlled, Study of the Safety and Efficacy of RGN-352 in Subjects With an Acute ST Elevation Myocardial Infarction (STEMI) After Occlusion of the Proximal Left Anterior Descending Coronary Artery

The objective of this study is to evaluate the safety and tolerability of two active doses of RGN-352 (thymosin beta 4, Tβ4, Injectable Solution) in patients with acute myocardial infarction receiving percutaneous coronary intervention angioplasty with or without stent placement. Approximately 75 subjects will be randomized to receive one of two RGN-352 doses of 1200 mg, or 450 mg, or placebo, administered iv by iv push daily for the first 3 consecutive days and weekly for 4 more weeks.

开始日期2019-07-01

申办/合作机构

RegeneRx Biopharmaceuticals, Inc.

NCT00743769 / Withdrawn临床1期

A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Phase 1 Study of the Safety and Tolerability of the Intravenous Administration of Thymosin Beta 4 and Its Pharmacokinetics After Single and Multiple Doses in Healthy Volunteers

The purpose of this study is to determine whether the intravenous administration of single- and multiple-ascending doses of Thymosin Beta 4 is safe and tolerable in healthy volunteers.

开始日期2008-04-01

申办/合作机构

RegeneRx Biopharmaceuticals, Inc.

NCT00832091 / Completed临床2期

A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Venous Stasis Ulcers

The purpose of this study is to evaluate the safety, tolerability and effectiveness of Thymosin Beta 4 administered topically in patients with Venous Stasis ulcers

开始日期2006-07-01

申办/合作机构

RegeneRx Biopharmaceuticals, Inc.

[+1]

100 项与 RegeneRx Biopharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 RegeneRx Biopharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

项与 RegeneRx Biopharmaceuticals, Inc. 相关的文献（医药）

2007-09-01·Annals of the New York Academy of Sciences2区 · 综合性期刊

Development of Thymosin β4 for Treatment of Patients with Ischemic Heart Disease

2区 · 综合性期刊

Article

作者: Crockford, David

Abstract: Thymosin beta 4 (Tβ4) is a highly conserved, 43‐amino acid acidic peptide (pI 4.6) that was first isolated from bovine thymus tissue over 25 years ago. It is present in most tissues and cell lines and is found in high concentrations in blood platelets, neutrophils, macrophages, and other lymphoid tissues. Tβ4 has numerous physiological functions, the most prominent of which being the regulation of actin polymerization in mammalian nucleated cells and with subsequent effects on actin cytoskeletal organization, necessary for cell motility, organogenesis, and other important cellular events. Recently, Tβ4 was shown to be expressed in the developing heart and found to stimulate migration of cardiomyocytes and endothelial cells, promote survival of cardiomyocytes (Nature, 2004), and most recently to play an essential role in all key stages of cardiac vessel development: vasculogenesis, angiogenesis, and arteriogenesis (Nature 2006). These results suggest that Tβ4 may have significant therapeutic potential in humans to protect myocardium and promote cardiomyocyte survival in the acute stages of ischemic heart disease. RegeneRx Biopharmaceuticals, Inc. is developing Tβ4 for the treatment of patients with acute myocardial infarction (AMI). Such efforts presented will include the formulation, development, and manufacture of a suitable drug product for use in the clinic, the performance of nonclinical pharmacology and toxicology studies, and the implementation of a phase 1 clinical protocol to assess the safety, tolerability, and the pharmacokinetics of Tβ4 in healthy volunteers. A phase 2 proof of principle clinical trial in AMI patients is in the planning stage and will not be presented at this time.

Thymosin α, thymosin β and analogs

作者: Goldstein, A. L. ; Wang, S. S. ; Wang, B. S. H.

A review, with 17 references

Peptide research

Cleavage and deprotection of peptide resins using chloro- and bromotrialkylsilanes

作者: Leopold, Eric J. ; Hughes, John L.

The cleavage of a peptide resin attached to a phenylacetomidomethyl (PAM) resin was investigated using bromotrimethylsilane (TMSBr) with thioanisole in trifluoroacetic acid (TFA), and by chlorotrimethylsilane (TMSCl) in the same reagents with lithium bromide.Both TMSBr and TMSCl cleaved the peptide from the resin, but TMSCl required elevated temperature (50°) to effect the cleavage.Procedures were investigated for the deprotection and cleavage of either Arg(Tos) or Arg(Mts) (Tos = tosyl, Mts = mesitylenesulfonyl) residues attached to 4-methylbenzhydrylamine (MBHA) resin, using either TMSCl or TMSBr as cleavage reagents.The Mts group is cleanly removed from Arg using TMSBr with thioanisole in TFA and by TMSCl in the same reagents with lithium bromide.

项与 RegeneRx Biopharmaceuticals, Inc. 相关的新闻（医药）

2023-08-15

·PRNewswire

RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations

ROCKVILLE, Md., Aug. 15, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, announced that it has today effected a 1-for-100 reverse split in the outstanding shares of Common Stock of the Company and has filed the requisite Form 15 to suspend and terminate the Company's continued obligations to file reports with the SEC pursuant to Sections 13(d) and 15(d) of the Securities Exchange Act of 1934, as amended. The Company expects that stockholders of record will receive information from the Company's transfer agent, American Stock Transfer & Trust Company, regarding exchange of pre-split stock certificates for post-split certificates and issuance of cash, if any, due for fractional shares canceled as a result of the reverse stock split. Stockholders owning the Company's Common Stock in "street name" should obtain this information from their respective broker-dealers. Future information of interest to stockholders may be posted periodically on the Company's website, . Any questions can be directed to Mr. J.J. Finkelstein at 301.208.9191 or by email to [email protected]. Forward-Looking Statements Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Please view risks described in the Company's past filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2022, and the subsequent quarterly reports filed on Form 10-Q, as well as other filings the Company has made with the SEC, prior to the date hereof. As the Company is no longer subject to SEC reporting, there is no assurance that the Company will maintain on its website or with broker-dealers the requisite current public information to permit public trading in the Company's Common Stock. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law. SOURCE RegeneRx Biopharmaceuticals, Inc.

2023-08-07

·PRNewswire

RegeneRx Receives Stockholder Approval for Reverse Stock Split

ROCKVILLE, Md., Aug. 7, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, announced that, pursuant to the company's consent solicitation dated July 11, 2023, it has received consents as of August 3, 2023 from the holders of 51.07% of the Company's Common Stock in favor of the proposed reverse stock split, which is a prerequisite to allowing the Company to suspend its public reporting obligations under the Securities Exchange Act of 1934 and become a non-reporting, privately held company. J.J. Finkelstein, the Company's CEO, commented, "We thank our stockholders for voting in favor of the proposed reverse stock split. We expect to effect a 1-for-100 reverse split in our outstanding shares of Common Stock on or about August 14, 2023. Promptly thereafter, we expect to file the requisite Forms 15 to suspend our continued obligations to file reports with the SEC pursuant to the Securities Exchange Act of 1934, as amended." Any questions can be directed to Mr. J.J. Finkelstein at 301.208.9191 or by email to [email protected]. Forward-Looking Statements Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Please view risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2022, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law. SOURCE RegeneRx Biopharmaceuticals, Inc.

2023-08-07

·BioSpace

RegeneRx Receives Stockholder Approval for Reverse Stock Split - August 07, 2023

ROCKVILLE, Md., Aug. 7, 2023 /PRNewswire/ --RegeneRx Biopharmaceuticals, Inc.(OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, announced that, pursuant to the company's consent solicitation dated July 11, 2023, it has received consents as of August 3, 2023 from the holders of 51.07% of the Company's Common Stock in favor of the proposed reverse stock split, which is a prerequisite to allowing the Company to suspend its public reporting obligations under the Securities Exchange Act of 1934 and become a non-reporting, privately held company. J.J. Finkelstein, the Company's CEO, commented, "We thank our stockholders for voting in favor of the proposed reverse stock split. We expect to effect a 1-for-100 reverse split in our outstanding shares of Common Stock on or about August 14, 2023. Promptly thereafter, we expect to requisite Forms 15 to suspend our continued obligations to with the SEC pursuant to the Securities Exchange Act of 1934, as amended." Any questions can be directed to Mr. J.J. Finkelstein at 301.208.9191 or by email to jjfnk@regenerx.com. Forward-Looking Statements Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Please view risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2022, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law. View original content: SOURCE RegeneRx Biopharmaceuticals, Inc. Company Codes: OTC-PINK:RGRX, OTC-BB:OTC, OTC-BB:RGRX

100 项与 RegeneRx Biopharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 RegeneRx Biopharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息